(Halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents

Expert Opinion on Therapeutic Patents

Volumn 13, Issue 3, 2003, Pages 381-385

[No Author Info available]

Author keywords

Mitogen activated protein kinase(MAPK); P38 MAPK; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; BENZENE DERIVATIVE; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ETANERCEPT; FUSED HETEROCYCLIC RINGS; INFLIXIMAB; INTERLEUKIN 1; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ROFECOXIB; TUMOR NECROSIS FACTOR ALPHA;

AUTOIMMUNE DISEASE; CLINICAL TRIAL; DISEASE MARKER; DRUG APPROVAL; DRUG EFFICACY; DRUG MARKETING; DRUG POTENCY; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; ENDOTOXEMIA; ENTERITIS; HUMAN; IMMUNOMODULATION; PATENT; PATHOGENESIS; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; STRUCTURE ACTIVITY RELATION; VALIDATION PROCESS;

EID: 0037352012     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/eotp.13.3.381.21335     Document Type: Review

References (17)

1. FIJEN JW, ZIJLSTRA JG, DE BOER P et al.: Suppression of the clinical and cytokine response to endotoxin by RWJ-67657, a p38 mitogen-activated protein-kinase inhibitor, in healthy human volunteers. Clin. Exp. Immunol. (2001) 124(1):16-20.
2. BRANGER J, VAN DEN BLINK B, WEIJER S et al.: Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. J. Immunol. (2002) 168(8):4070-4077.
3. MELDRUM DR: Tumor necrosis factor in the heart. Am. J. Physiol. (1998) 274(3):R577-R595.
4. GAO FT, YUE TL, SHI DW et al.: p38 MAPK inhibition reduces myocardial reperfusion injury via inhibition of endothelial adhesion molecule expression and blockade of PMN accumulation. Cardiovasc. Res. (2002) 53(2):414-422.
5. MOCANU MM, BAXTER GF, YUE Y, CRITZ S, YELLON D: The p38 MAPK inhibitor, SB203580, abrogates ischaemic preconditioning in rat heart but timing of administration is critical. Basic Res. Cardiol. (2000) 95:472-478.
6. NAKANO A, COHEN MV, CRITZ S, DOWNEY JM: SB 203580, an inhibitor of p38 MAPK, abolishes infarct-limiting effect of ischemic preconditioning in isolated rabbit hearts. Basic Res. Cardiol. (2000) 95(6):466-471.
7. BADGER AM, BRADBEER JN, VOTTA B, LEE JC, ADAMS JL, GRISWOLD DE: Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J. Pharmacol. Exp. Ther. (1996) 279(3):1453-1461.
8. SANO I, TAKAHASHI T, KOJI T, UDONO H, YUI K, AYABE H: Prolonged survival of rat cardiac allograft with proinflammatory cytokine inhibitor. J. Heart Lung Transplant (2001) 20(5):583-589.
9. JARRAR D, WANG P, SONG GY, CIOFFI WG, BLAND KI, CHAUDRY I: Inhibition of tyrosine kinase signaling after trauma-hemorrhage: a novel approach for improving organ function and decreasing susceptibility to subsequent sepsis. Ann. Surg. (2000) 231(3):399-407.
10. DUNN SL, YOUNG EA, HALL MD, MCNULTY S: Activation of astrocyte intracellular signaling pathways by interleukin-1 in rat primary striatal cultures. Glia (2002) 37(1):31-42.
11. ZHU J, ROTTKAMP CA, HARTZLER A et al.: Activation of MKK6, an upstream activator of p38, in Alzheimer's disease. J. Neurochem. (2001) 79(2):311-318.
12. D'AVERSA TG, WEIDENHEIM KM, BERMAN JW: CD40-CD40L interactions induce chemokine expression by human microglia: implications for human immunodeficiency virus encephalitis and multiple sclerosis. Am. J. Pathol. (2002) 160(2):559-567.
13. WILMER WA, DIXON CL, HEBERT C: Chronic exposure of human mesangial cells to high glucose environments activates the p38 MAPK pathway. Kidney Int. (2001) 60(3):858-871.
14. PUIGSERVER P, RHEE J, LIN J: Cytokine stimulation of energy expenditure through p38 MAP kinase activation of PPARγ coactivator-1. Mol. Cell (2001) 8(5):971-982.
15. MANDELKAR S, KONG AN: Mechanisms of tamoxifen-induced apoptosis. Apoptosis (2001) 6(6):469-477.
16. SIMON C, SIMON M, VUCELIC G: The p38 SAPK pathway regulates the expression of the MMP-9 collagenase via AP-1-dependent promoter activation. Exp. Cell Res. (2001) 271(2):344-355.
17. PURVES TA, MIDDLEMAS TA, AGTHONG S: A role for mitogen-activated protein kinases in the etiology of diabetic neuropathy. FASEB J. (2001) 15(13):2508-2514.